Newron Pharmaceuticals S.p.A.
NP5
Rank in Stocks
#16084
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Share Price
$11.18
Last synced: 2026-11-09
Market Cap
$228.56M
Change (1 day)
3.58%
Change (1 year)
-37.51%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Newron Pharmaceuticals S.p.A. (NP5)
Category
Healthcare
EPS for Newron Pharmaceuticals S.p.A. (NP5)
EPS as of June 2026 TTM: $-1.62
According to Newron Pharmaceuticals S.p.A.'s latest financial reports, its current EPS (TTM) is $-1.62. At the end of 2025 the company had an EPS of $-0.79, a decrease compared to its 2024 EPS of $0.88.
EPS history for Newron Pharmaceuticals S.p.A. from 2005 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.62 | 104.68% |
| 2025 | $-0.79 | -188.88% |
| 2024 | $0.88 | -187.92% |
| 2023 | $-1.01 | -4.30% |
| 2022 | $-1.05 | 10.05% |
| 2021 | $-0.96 | -33.53% |
| 2020 | $-1.44 | 13.35% |
| 2019 | $-1.27 | 31.34% |
| 2018 | $-0.97 | 151.38% |
| 2017 | $-0.38 | -64.91% |
| 2016 | $-1.09 | -39.29% |
| 2015 | $-1.80 | 86.21% |
| 2014 | $-0.97 | 13.54% |
| 2013 | $-0.85 | 122.90% |
| 2012 | $-0.38 | -66.80% |
| 2011 | $-1.15 | -72.29% |
| 2010 | $-4.16 | -24.87% |
| 2009 | $-5.53 | 44.94% |
| 2008 | $-3.82 | 37.49% |
| 2007 | $-2.78 | -51.25% |
| 2006 | $-5.70 | -8.85% |
| 2005 | $-6.25 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,068.46% |
US
|
|
| $-7.07 | 337.23% |
US
|
|
| $-5.29 | 227.15% |
AU
|
|
| $12.88 | -896.54% |
BE
|
|
| $21.56 | -1,433.33% |
NL
|
Questions about Newron Pharmaceuticals S.p.A.'s earnings per share (EPS)
What is Newron Pharmaceuticals S.p.A.'s earnings per share (EPS)?
Newron Pharmaceuticals S.p.A.'s earnings per share (EPS) over the last twelve months is $-1.62, as of Jun 2026.
What was Newron Pharmaceuticals S.p.A.'s earnings per share (EPS) in 2025?
In 2025, Newron Pharmaceuticals S.p.A.'s earnings per share (EPS) was $-0.79, compared with $0.88 in 2024.
How has Newron Pharmaceuticals S.p.A.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Newron Pharmaceuticals S.p.A.'s earnings per share (EPS) was highest in 2024 ($0.88) and lowest in 2020 ($-1.44).
How does Newron Pharmaceuticals S.p.A.'s earnings per share (EPS) compare with similar companies?
Newron Pharmaceuticals S.p.A.'s earnings per share (EPS) ($-1.62) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.